Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
POINT is a randomized, double-blind, multicenter clinical trial to determine whether clopidogrel (Plavix®) is effective in preventing major ischemic vascular events such as ischemic stroke and myocardial infarction in newly-diagnosed patients with TIA and minor ischemic stroke. Study participants are enrolled within 12 hours of their symptom onset and presentation to the emergency department and are then followed for 90 days after randomization.
Johns Hopkins is participating along with up to 350 other investigational sites in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and the NETT Network. The study. which started in 2010, will enroll 5840 participants over approximately 7 years.
Johns Hopkins' Principal Investigator
Victor Urrutia, MD